Integral Molecular, a leader in antibody discovery and characterization, has published new research in the journal mAbs, revealing that as many as one-third of antibody-based drugs exhibit nonspecific binding to unintended targets.
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide | Psychedelic Invest
SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing